China
Ambispective Observational Study
Medical records
548
548 hospitalized COVID-19 patients
none
Total
15 Day
COVID-19 (death)
78
Death within 15 days of hospitalization.
Treatment
Treatment for COVID-19
Lopinavir/ritonavir was associated with decreased mortality.
Not received
Treated with Lopinavir–Ritonavir
Hazard ratio
0.350 (0.150-0.830)
Yes
No
Risk was adjusted for Age, oxygen saturation (SaO2), WBC, Lymphocyte (count and time), LDH, and multiorgan dysfunction, Glucocorticoid treatment, lopinavir/ritonavir treatment, arbidol treatment, ribavirin treatment.
14.2% patients of this cohort reached the primary endpoint of death within 15-day hospitalization. Aging, hypoxia, lymphopenia, high LDH level and multiple organ dysfunction were associated with increased 15-day in-hospital mortality from COVID-19. Lopinavir/ritonavir was associated with decreased mortality. Among the critically ill patients, the hazard ratio was not reduced in those receiving invasive ventilation versus non-invasive ventilation.
Good